Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study

Tanioka,Hiroaki; Asano,Motoi; Yoshida,Ryousuke; Waki,Naohisa; Uno,Futoshi; Ishizaki,Masahiro; Yamashita,Kazuki; Morishita,Yuki; Nagasaka,Takeshi

doi:10.3892/ol.2018.9127

Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study

Authors:
- Hiroaki Tanioka
- Motoi Asano
- Ryousuke Yoshida
- Naohisa Waki
- Futoshi Uno
- Masahiro Ishizaki
- Kazuki Yamashita
- Yuki Morishita
- Takeshi Nagasaka
View Affiliations

Affiliations: Department of Medical Oncology, Okayama Rosai Hospital, Okayama 702‑8055, Japan, Department of Surgery, Okayama Rosai Hospital, Okayama 702‑8055, Japan, Department of Pharmacy, Okayama Rosai Hospital, Okayama 702‑8055, Japan, Department of Clinical Oncology, Kawasaki Medical School Hospital, Okayama 701‑0192, Japan
Published online on: July 11, 2018 https://doi.org/10.3892/ol.2018.9127
Pages: 3674-3680
Copyright: © Tanioka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical benefits of cetuximab retreatment in patients with metastatic colorectal (mCRC) have been reported. In the present study, the effect of cetuximab retreatment on predictive markers was investigated by evaluating the clinical benefit of initial cetuximab treatment prior to cetuximab retreatment. Between November 2012 and March 2017, 14 patients with KRAS proto‑oncogene GTPase exon 2 wild‑type mCRC who exhibited a clinical benefit (confirmed stable disease for at least 6 months or a clinical response) to an initial cetuximab‑based regimen, who received multiple lines of chemotherapy following disease progression and ultimately received a second cetuximab and irinotecan regimen, were retrospectively analyzed. For retreatment, patients received bi‑weekly irinotecan (120‑150 mg/m2) combined with cetuximab (400 mg/m2 as an initial dose, followed by 250 mg/m2, weekly). The median age of the 14 patients (11 males, 3 females) was 68 years (32‑77). The median progression‑free survival (PFS) following prior cetuximab‑based therapy was 6.6 months (range, 4.1‑18.4). Initial cetuximab treatment was administered as a first‑line treatment in 11 patients, a second‑line treatment in 1 patient and a third‑line treatment in 2 patients. The median interval time between the last cycle of initial cetuximab‑based therapy and the first cycle of cetuximab retreatment was 13.1 months (range, 6.0‑37.1). The objective response rate of cetuximab retreatment was 21.4% and the median PFS was 4.4 months (95% confidence interval, 1.4‑5.6). The Spearman's correlation coefficient for the PFS following retreatment and duration of initial cetuximab‑based regimens demonstrated a more marked correlation compared with that between the PFS following retreatment and the interval time between the two regimens (r=0.45, P=0.11 vs. r=0.08, P=0.79). Cetuximab retreatment may provide clinical benefit to patients with mCRC who were good responders with longer periods of initial cetuximab‑based therapy.

View Figures

View References

1	Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T and Nishimoto H: Japan Cancer Surveillance Research Group: Cancer incidence and incidence rates in Japan in 2008: A study of 25 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 44:388–396. 2014. View Article : Google Scholar : PubMed/NCBI
2	Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI
3	National Comprehensive Cancer Network (NCCN): NCCN Guidelines for Colon cancer (version 2, 2017). http://www.nccn.org/professionals/physician_gls/f_guidelines.aspNovember 09–2017
4	Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aguilar Aranda E, Bardelli A, Benson A, Bodoky G, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
5	Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
6	Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet. Oncol. 17:1426–1434. 2016.
7	Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015. View Article : Google Scholar : PubMed/NCBI
8	Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312. 2013. View Article : Google Scholar : PubMed/NCBI
9	Takeuchi N, Koike K, Yoshida S, Kudo A, Sekiguchi N, Nakayama A, Kubota K, Rokuhara T and Kitahara M: Treatment of metastatic refractory colorectal cancer following regorafenib failure. Mol Clin Oncol. 7:308–312. 2017.PubMed/NCBI
10	Rossini D, Santini D, Cremolini C, Salvatore L, Lonardi S, Aquila ED, Aprile G, Loupakis F, Vincenzi B, Battaglin F, et al: Rechallenge with cetuximab + irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with acquired resistance to 1st-line cetuximab + irinotecan: The phase II CRICKET study by GONO. Ann Oncol. 28 Suppl 3:iii1–iii12. 2017. View Article : Google Scholar
11	Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, et al: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? Ann Oncol. 23:2313–2318. 2012. View Article : Google Scholar : PubMed/NCBI
12	Tsuji A, Eto T, Masuishi T, Satake HS, Segawa Y, Tanioka H, Hara H, Kotaka M, Sagawa T, Watanabe T, et al: Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08). Ann Oncol. 27:510P2016. View Article : Google Scholar
13	Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, et al: Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 15:7132015. View Article : Google Scholar : PubMed/NCBI
14	National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE). v4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40May 17–2010
15	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
16	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
17	Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
18	Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 486:537–540. 2012. View Article : Google Scholar : PubMed/NCBI
19	Price T, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X and Peeters M: Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. Eur J Cancer. 68:51–59. 2016. View Article : Google Scholar : PubMed/NCBI
20	Taniguchi H, Komori A, Narita Y, Kadowaki S, Ura T, Andoh M, Yatabe Y, Komori K, Kimura K, Kinoshita T and Muro K: A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer. Jpn J Clin Oncol. 46:228–233. 2016. View Article : Google Scholar : PubMed/NCBI
21	Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, et al: Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 17:142012. View Article : Google Scholar : PubMed/NCBI